Centessa Pharmaceuticals plc
DelistedCIK 1847903fmd_1BT1X4V394TX3CGJGD160ZN70TManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Mar 31, 2026, 25 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 7 | 0 | 15 |
| Research and development | 4 | 9 | – | 155 | 124 | 150 | 172 |
| Operating income | (5) | (10) | – | (212) | (171) | (201) | (208) |
| Interest expense | – | – | – | 7 | 10 | 10 | 11 |
| Interest and investment income | – | – | – | – | 10 | 14 | 21 |
| Other non-operating income (expense) | 0 | 0 | – | 2 | (5) | (2) | 3 |
| Income before taxes | (5) | (11) | – | (217) | (176) | (233) | (196) |
| Income tax expense | 0 | 0 | 0 | (1) | (25) | 3 | 2 |
| Net income from continuing operations | (5) | (11) | – | (216) | (151) | (236) | (198) |
| Net income | (5) | (11) | – | (216) | (151) | (236) | (198) |